- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Becky Wong, PharmD, MBA
Medical Science Director

E. Jeffrey Greenberg, MD
Neurologist at Princeton & Rutgers Neurology, P.A., Co-Founder of Advanced Clinical Institute
More

Jaclyn Beckinghausen
Becky Wong, PharmD, MBA and Jaclyn Beckinghausen are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
E. Jeffrey Greenberg, MD is a paid speaker for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)